524 related articles for article (PubMed ID: 2527074)
21. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
[TBL] [Abstract][Full Text] [Related]
22. A novel inhibitory prostanoid receptor in piglet saphenous vein.
Coleman RA; Grix SP; Head SA; Louttit JB; Mallett A; Sheldrick RL
Prostaglandins; 1994 Feb; 47(2):151-68. PubMed ID: 8016385
[TBL] [Abstract][Full Text] [Related]
23. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles.
Ogletree ML; Allen GT
J Pharmacol Exp Ther; 1992 Feb; 260(2):789-94. PubMed ID: 1531361
[TBL] [Abstract][Full Text] [Related]
24. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
Keery RJ; Lumley P
Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
Hamid-Bloomfield S; Whittle BJ
Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological actions of ICI 180080, a novel thromboxane receptor antagonist.
Jessup CL; Jessup R; Wayne M
J Pharm Pharmacol; 1986 Oct; 38(10):754-7. PubMed ID: 2878996
[TBL] [Abstract][Full Text] [Related]
27. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
Karasawa A; Shirakura S; Higo K; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
[TBL] [Abstract][Full Text] [Related]
28. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
Imura Y; Terashita Z; Shibouta Y; Nishikawa K
Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770
[TBL] [Abstract][Full Text] [Related]
29. Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide.
Kemp BK; McPherson GA
Eur J Pharmacol; 1998 Aug; 354(2-3):173-8. PubMed ID: 9754918
[TBL] [Abstract][Full Text] [Related]
30. Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction.
Molimard M; Martin CA; Naline E; Hirsch A; Advenier C
Eur J Pharmacol; 1995 May; 278(1):49-54. PubMed ID: 7545124
[TBL] [Abstract][Full Text] [Related]
31. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological evaluation of the beta-adrenoceptor agonist and thromboxane receptor blocking properties of 1-benzyl substituted trimetoquinol analogues.
Shams G; Romstedt KJ; Gerhardt MA; Harrold MW; Miller DD; Feller DR
Eur J Pharmacol; 1990 Aug; 184(1):21-31. PubMed ID: 1976530
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
35. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
37. Effect of GR32191 and other thromboxane receptor blocking drugs on human platelet deposition onto de-endothelialized arteries.
Foster MR; Hornby EJ; Stratton LE
Thromb Res; 1992 Mar; 65(6):769-84. PubMed ID: 1386166
[TBL] [Abstract][Full Text] [Related]
38. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors.
Coleman RA; Sheldrick RL
Br J Pharmacol; 1989 Mar; 96(3):688-92. PubMed ID: 2720298
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
Armstrong RA; Jones RL; MacDermot J; Wilson NH
Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
[TBL] [Abstract][Full Text] [Related]
40. Reduction in the number of thromboxane receptors on human platelets after exposure to GR32191.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):548-52. PubMed ID: 8242229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
